P4.049 Lopinavir/Ritonavir in Combination with Tenofovir/Emtricitabine as Post Exposure Prophylaxis (PEP) to HIV - an Effective and Well Tolerated Regimen
P4.049 Lopinavir/Ritonavir in Combination with Tenofovir/Emtricitabine as Post Exposure Prophylaxis (PEP) to HIV - an Effective and Well Tolerated Regimen
复制标题
P4.049 洛匹那韦/利托那韦联合替诺福韦/恩曲他滨作为 HIV 暴露后预防 (PEP) - 一种有效且耐受性良好的方案
DOI：
10.1136/sextrans-2013-051184.0947
复制
发表时间：
2013
影响因子：
3.6
通讯作者：
Ahmad Jalili
中科院分区：
文献类型：
--
作者：
M. Schreiner;Georg Stingl;Armin Rieger;Ahmad Jalili
PEP是一种抗逆转录病毒药物的疗程，在暴露于艾滋病毒的高风险事件发生后72小时内给予，旨在降低已建立感染的几率。我们评估了2008-2012年转诊至维也纳医科大学综合医院并指示进行PEP的假定HIV暴露个体。方法和结果我们分析了450人的数据。我们的数据表明：44.1%为女性，适应症类型：无保护的同性恋接触[28.5%，其中45%的源患者（SP）是艾滋病毒阳性]，针刺伤害（22.8%，37.5%艾滋病毒阳性的性传播感染者），无保护的异性性接触（21.4%，20%艾滋病毒阳性的SP），职业接触（12.8%，100%艾滋病毒阳性的性传播感染者），强奸（11.4%）和静脉注射吸毒者交换针头（2.8%）SP的HIV状态未知，PEP方案为洛匹那韦/利托那韦联合替诺福韦/恩曲他滨（79.4%），地瑞那韦/利托那韦联合替诺福韦/恩曲他滨（10.1%）或洛匹那韦/利托那韦联合拉米夫定/齐多夫定（10.5%），58.8%的个体耐受PEP，无任何不良事件，35.3%有轻微不良事件（恶心、疲劳、腹泻、腹部不适或胰腺酶轻微升高），5.8%的PEP被修改或中止（严重不良事件：强烈腹泻、腹痛和呕吐或肝功能参数显著升高），77.1%的患者错过了PEP开始后1、3和6个月计划的至少一次随访，未观察到血清转换病例。结论寻求PEP咨询服务的性别数量大致相同。最常见的接触类型包括高风险性接触和针刺伤害。洛匹那韦/利托那韦联合替诺福韦/恩曲他滨似乎是一种耐受性良好且有效的治疗方法。
Introduction PEP to HIV is a course of antiretroviral drugs administered within 72 hrs after events with high risk of exposure to HIV aiming to reduce the odds of established infection. We evaluated the putative HIV exposed individuals referred to the Medical university of Vienna general hospital and indicated for PEP in years 2008–2012. Methodology and Results We have analysed the data from 450 individuals. Our data demonstrates that: 44.1% are females, indication type: unprotected homosexual contact [28.5%, from which 45% of source patients (SPs) were HIV positive], needlestick injuries (22.8%, 37.5% HIV positive SPs), unprotected heterosexual contact (21.4%, 20% HIV positive SPs), occupational exposure (12.8%, 100% HIV positive SPs), rape (11.4%) and needle exchange by IVDUs (2.8%) where HIV status of SPs were unknown, PEP regimens were combination of lopinavir/ritonavir with tenofovir/emtricitabine (79.4%), darunavir/ritonavir with tenofovir/emtricitabine (10.1%) or lopinavir/ritonavir with lamivudine/zidovudine (10.5%), 58.8% of individuals tolerated the PEP without any adverse events, 35.3% had minor adverse events (nausea, fatigue, diarrhoea, abdominal discomfort or slight elevation of pancreatic enzymes) and in 5.8% PEP was modified or discontinued (severe adverse events: strong diarrhoea, abdominal pain and vomiting or significant elevation of liver function parameters), 77.1% of patients missed at least one of their follow-up visits planned at 1, 3 and 6 months after PEP start, and no case of seroconversion was observed. Conclusion Approximately equal numbers of sexes seek counselling service for PEP. Most prevalent types of exposure include high risk sexual contact and needlestick injuries. Lopinavir/ritonavir with tenofovir/emtricitabine combination seems to be a well tolerated and effective therapy.